TaiMed BiologicsROCO:4147 55 Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued). Among 148 Biotechnology companies, TaiMed Biologics ranks worse than 675675% on this metric.
As of today (2026-07-11), the Forward Annual Dividend Yield of TaiMed Biologics is 0.00%.
As of today (2026-07-11), the Trailing Annual Dividend Yield of TaiMed Biologics is 0.00%.
ROCO:4147's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
TaiMed Biologics (ROCO:4147) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
TaiMed Biologics Forward Dividend Yield % Related Terms
ROCO:4147 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, TaiMed Biologics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
TaiMed Biologics (ROCO:4147) has a Forward Dividend Yield % of 0.00% as of Jul. 11, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #999999 out of 148 companies in the Biotechnology industry.
Is TaiMed Biologics' Forward Dividend Yield % too high?
TaiMed Biologics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, TaiMed Biologics ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #999999 out of 148 companies for Forward Dividend Yield %. This places TaiMed Biologics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.31, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Forward Dividend Yield %: 0.00%
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 